• Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers.
• Results have not been presented; topline data are expected in Q1 2027.
• Study aims to show Nu-3 can control infection at the wound site, supporting its path toward mid-stage development.
• Readouts are intended to guide dose selection, positioning the program for a Phase 2b trial against placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY55438) on September 24, 2026, and is solely responsible for the information contained therein.